IN2012DN02692A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02692A
IN2012DN02692A IN2692DEN2012A IN2012DN02692A IN 2012DN02692 A IN2012DN02692 A IN 2012DN02692A IN 2692DEN2012 A IN2692DEN2012 A IN 2692DEN2012A IN 2012DN02692 A IN2012DN02692 A IN 2012DN02692A
Authority
IN
India
Prior art keywords
subunit
immunity against
inducing immunity
antigenic peptides
antibody
Prior art date
Application number
Inventor
Alice P Taylor
Body Makabi-Panzu
David M Goldenberg
Original Assignee
Ct Molecular Med & Immunology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/754,140 external-priority patent/US8722047B2/en
Priority claimed from US12/754,740 external-priority patent/US8562988B2/en
Application filed by Ct Molecular Med & Immunology filed Critical Ct Molecular Med & Immunology
Publication of IN2012DN02692A publication Critical patent/IN2012DN02692A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Abstract

The present invention concerns methods and compositions for subunit-based vaccines for inducing immunity against poxvirus infections, such as smallpox. Preferred embodiments concern immunoconjugates comprising one or more subunit antigenic peptides attached to an antibody or fragment thereof that targets antigen-producing cells (APCs). More preferably, the antibody binds to HLA-DR and the antigenic peptide is from an immunomodulating factor, such as the viral IL-18 binding protein (vIL18BP). However, mixtures of antigenic peptides from different viral proteins may also be used. The vaccine is capable of inducing immunity against poxvirus without risk of disseminated infection in immunocompromised hosts or transmission to susceptible contacts.
IN2692DEN2012 2009-11-05 2010-10-29 IN2012DN02692A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US25836909P 2009-11-05 2009-11-05
US25872909P 2009-11-06 2009-11-06
US12/754,140 US8722047B2 (en) 2005-03-03 2010-04-05 Humanized anti-HLA-DR antibodies
US12/754,740 US8562988B2 (en) 2005-10-19 2010-04-06 Strategies for improved cancer vaccines
US37805910P 2010-08-30 2010-08-30
PCT/US2010/054668 WO2011056721A2 (en) 2009-11-05 2010-10-29 Immunoconjugates comprising poxvirus-derived peptides and antibodies against antigen-presenting cells for subunit-based poxvirus vaccines

Publications (1)

Publication Number Publication Date
IN2012DN02692A true IN2012DN02692A (en) 2015-09-04

Family

ID=43970701

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2692DEN2012 IN2012DN02692A (en) 2009-11-05 2010-10-29

Country Status (6)

Country Link
EP (1) EP2496256A4 (en)
CN (1) CN102573902A (en)
AU (1) AU2010315432A1 (en)
CA (1) CA2776563A1 (en)
IN (1) IN2012DN02692A (en)
WO (1) WO2011056721A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6130307B2 (en) 2011-03-17 2017-05-17 ザ ユニバーシティ オブ バーミンガム Redirected immunotherapy
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
WO2014047124A1 (en) * 2012-09-18 2014-03-27 University Of Washington Through Its Center For Commercialization Compositions and methods for delivery of antigens to plasmacytoid dendritic cells
CA2971288A1 (en) 2015-02-02 2016-08-11 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes
EP3377103B1 (en) 2015-11-19 2021-03-17 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
CN109172818B (en) * 2018-08-02 2021-10-22 浙江康佰裕生物科技有限公司 Protein vaccinia vaccine and efficacy detection method thereof
CN109187982B (en) * 2018-08-02 2021-06-04 浙江康佰裕生物科技有限公司 Method for screening and identifying TLR vaccine adjuvant
CN113347993A (en) * 2018-10-22 2021-09-03 艾赛澳克莱克斯疗法有限责任公司 Mutant vaccinia virus and uses thereof
CN111474339A (en) * 2020-04-17 2020-07-31 浙江康佰裕生物科技有限公司 Method for labeling poxvirus particles by fluorescence and application thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5194254A (en) * 1986-05-06 1993-03-16 Connaught Laboratories Limited Enhancement of antigen immunogenicity
WO1994006469A1 (en) * 1992-09-18 1994-03-31 La Jolla Institute For Allergy And Immunology Hiv fusion polypeptide
AU6117896A (en) * 1995-06-07 1996-12-30 Connaught Laboratories Limited Chimeric antibodies for delivery of antigens to selected cel ls of the immune system
ATE395422T1 (en) * 1995-06-07 2008-05-15 Sanofi Pasteur Ltd CHIMERIC ANTIBODIES FOR DELIVERY OF ANTIGENS TO SELECTED CELLS OF THE IMMUNE SYSTEM
US6224870B1 (en) * 1997-01-24 2001-05-01 Genitrix, Ltd. Vaccine compositions and methods of modulating immune responses
US7138103B2 (en) * 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US7534866B2 (en) * 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US7527787B2 (en) * 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
US7666400B2 (en) * 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
US6958214B2 (en) * 2000-07-10 2005-10-25 Sequenom, Inc. Polymorphic kinase anchor proteins and nucleic acids encoding the same
KR101017732B1 (en) 2002-03-01 2011-02-28 이뮤노메딕스, 인코오포레이티드 Internalizing anti-CD74 antibodies and methods of use
EP1501863A4 (en) * 2002-05-03 2007-01-24 Sequenom Inc Kinase anchor protein muteins, peptides thereof, and related methods
US7906118B2 (en) * 2005-04-06 2011-03-15 Ibc Pharmaceuticals, Inc. Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (DNL) technology
EP1618181B1 (en) * 2003-04-22 2014-10-15 IBC Pharmaceuticals Polyvalent protein complex
AU2006218454B2 (en) * 2005-03-03 2011-11-17 Immunomedics, Inc. Humanized L243 antibodies
AU2006232310B9 (en) * 2005-04-06 2011-07-21 Ibc Pharmaceuticals, Inc. Improved stably tethered structures of defined compositions with multiple functions or binding specificities
CN101484182B (en) * 2005-04-06 2014-06-11 Ibc药品公司 Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US20090269365A1 (en) * 2005-04-20 2009-10-29 University Of Washington Immunogenic vaccinia peptides and methods of using same
CA2607056C (en) * 2005-10-19 2015-11-24 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
CA2633486C (en) * 2005-12-16 2015-02-03 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
EP2016173A4 (en) * 2006-05-15 2010-06-09 Immunomedics Inc Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments
WO2009126558A1 (en) * 2008-04-10 2009-10-15 Ibc Pharmaceuticals, Inc. Modular method to prepare tetrameric cytokines with improved pharmacokinetics by the dock-and-lock (dnl) technology

Also Published As

Publication number Publication date
EP2496256A4 (en) 2013-07-17
WO2011056721A2 (en) 2011-05-12
CN102573902A (en) 2012-07-11
EP2496256A2 (en) 2012-09-12
CA2776563A1 (en) 2011-05-12
AU2010315432A1 (en) 2012-04-12
WO2011056721A3 (en) 2011-10-13

Similar Documents

Publication Publication Date Title
IN2012DN02692A (en)
MX2021011687A (en) Immunogenic compositions and vaccines comprising african swine fever virus peptides and proteins and uses thereof.
MX350274B (en) Vaccines for hsv-2.
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
DK2280721T3 (en) Indoleamin-2,3-dioxygenase-based immunotherapy
CO6480995A2 (en) NEW PROTEIN CONSTRUCTIONS OF THE HUMAN PAILOMA VIRUS (HPV) AND ITS USE IN THE PREVENTION OF HPV DISEASE
IN2014DN10288A (en)
WO2012034025A3 (en) Human cytomegalovirus vaccine
WO2007008918A3 (en) Virus vaccines comprising envelope-bound immunomodulatory proteins and methods of use thereof
PE20190420A1 (en) SOLUBLE AND STABILIZED RESPIRATORY SYNCITIAL VIRUS (RSV) PREFUSION PROTEINS F
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
MX344103B (en) Newcastle disease virus vectored herpesvirus vaccines.
PT1951300E (en) Changing th1/th2 balance in split influenza vaccines with adjuvants
MX2019003682A (en) Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same.
PH12015500308B1 (en) Hepatitis b virus core protein and surface antigen protein and vaccine comprising the same
EA201892735A1 (en) COMPOSITION OF VACCINE AGAINST HIV
WO2008103819A3 (en) Chimeric newcastle disease virus vlps
WO2008134643A3 (en) Trypanosoma antigens, vaccine compositions, and related methods
WO2016116905A9 (en) Cmv antigens and uses thereof
NZ601609A (en) Vaccine vectors and methods of enhancing immune responses
MX2022000222A (en) Prrsv minor protein-containing recombinant viral vectors and methods of making and use thereof.
TW200637573A (en) Peptide for delivery of mucosal vaccines
ZA201603187B (en) Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors
CY1125328T1 (en) RECOMBINANT FELINE LEUKEMIA VIRUS VACCINE CONTAINING AN OPTIMIZED FELINE LEUKEMIA VIRUS ENVELOPE GENE
CR11537A (en) VACCINE